{"id":2237,"date":"2013-04-01T12:09:00","date_gmt":"2013-04-01T10:09:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2013\/in-eigener-sache-5"},"modified":"2013-04-01T12:09:00","modified_gmt":"2013-04-01T10:09:00","slug":"in-eigener-sache-5","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2013\/in-eigener-sache-5","title":{"rendered":"In eigener Sache"},"content":{"rendered":"<p>Prof. Dr. med. Wolf-Dieter Ludwig ist im Januar 2013 vom Rat der Europ\u00e4ischen Union (EU) f\u00fcr das Management Board der Europ\u00e4ischen Arzneimittel-Agentur (EMA) nominiert worden. Er wurde f\u00fcr dieses Gremium von dem Comit\u00e9 Permanent des M\u00e9decins Europ\u00e9ens (CPME) vorgeschlagen und vertritt dort den \u00e4rztlichen Berufsstand. Das Management Board hat 35 Mitglieder, darunter Vertreter der 27 [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Prof. Dr. med. Wolf-Dieter Ludwig ist im Januar 2013 vom Rat der Europ\u00e4ischen Union (EU) f\u00fcr das Management Board der Europ\u00e4ischen Arzneimittel-Agentur (EMA) nominiert worden. Er wurde f\u00fcr dieses Gremium von dem Comit\u00e9 Permanent des M\u00e9decins Europ\u00e9ens (CPME) vorgeschlagen und vertritt dort den \u00e4rztlichen Berufsstand. Das Management Board hat 35 Mitglieder, darunter Vertreter der 27 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1284,4475],"class_list":["post-2237","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-ema","tag-prof-dr-w-d-ludwig"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2237","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2237"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2237\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2237"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2237"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2237"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}